MA-EUROIMMUN
1.4.2021 14:02:06 CEST | Business Wire | Press release
EUROIMMUN , a PerkinElmer, Inc. Company, today announced the launch of the SARS-CoV-2 NeutraLISA™ assay, a surrogate neutralization test intended for the detection of neutralizing antibodies against SARS-CoV-2, the pathogen causing COVID-19. The CE marked assay adds to the Company’s broad portfolio of COVID-19 diagnostics and is currently available in more than 30 countries that accept the CE mark.
In COVID-19, antibodies that target the viral receptor binding domain (RBD) in the S1 domain of the SARS-CoV-2 spike protein have been shown to exhibit a virus-neutralizing capacity, which predominately are IgG antibodies.
SARS-CoV-2 enters a human host cell through interaction of its RBD with the host cell ACE2 receptor. However, if the RBD is blocked by specific antibodies formed during immune response, the virus cannot continue to infect and proliferate within the human body. This is why many leading COVID-19 vaccine developments are also based on this protein domain.
The EUROIMMUN SARS-CoV-2 NeutraLISA imitates this natural process by determining the inhibitory effect of antibodies capable of hampering the interaction between biochemically produced RBD and ACE2. Unlike standard neutralization tests, which can be labor-intensive and require handling of the live virus in a specialized high-safety laboratory setting, the SARS-CoV-2-NeutraLISA assay is based on well-established ELISA technology and uses non-pathogenic viral proteins. As such, the assay can be processed in common lab settings either manually or automatically.
“In addition to disturbing or altogether inhibiting the pathogen from binding to a host cell, neutralizing antibodies may last for years in the human body and can potentially prevent SARS-CoV-2 infection and reinfection,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN. “The SARS-CoV-2 NeutraLISA assay supplements EUROIMMUN’s existing CE-marked QuantiVac™ ELISA and SARS-CoV-2 Interferon-gamma Release Assay which is expected to be available with CE mark soon. In combination, the assays make a powerful trio to help evaluate the immune response to SARS-CoV-2 induced through natural infection or vaccination with S1/RBD-based vaccines from multiple angles.”
EUROIMMUN offers a comprehensive COVID-19 product portfolio, including real-time PCR tests , an antigen detection assay for acute diagnostics, multiple antibody tests and a dried blood spot solution to support assessment of the immune response. In addition, EUROIMMUN offers the Interferon-gamma Release Assay to evaluate specific T-cell response, currently available for research use only, and provides automation systems for small, medium and high sample throughput workflows.
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005210/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Unveils a Global Framework to Protect Critical Organisations from Frontier AI Attacks1.10.2026 13:18:00 CEST | Press release
Thales believes that frontier models call for a revolution in the pace of cyber defence: while the fundamentals of cybersecurity remain valid, they must now be executed at machine speed, without ever relinquishing human judgement over the decisions that matter.Today, Thales unveiled an end-to-end framework to help critical organisations counter a new generation of cyber threats, spanning application security, detection and response, a global cyber defence platform, continuous evaluation and critical-asset resilience.As adversaries attack, adapt and multiply at machine speed, simply stacking isolated tools is no longer enough. Thales positions AI-driven, automated defence under human oversight as an essential evolution of cyber defence. At the Thales Cyber Summit held in Paris (France) , Thales today unveiled a global response to the challenges created by Frontier AI models. Reasoning, autonomy and scale of these cutting-edge systems far exceed previous generations, and can accelerate v
MidOcean Concludes 2026 Equity Raise, Securing More Than $4 Billion of Equity Commitments to Accelerate Global LNG Growth Strategy1.10.2026 13:00:00 CEST | Press release
MidOcean Energy ("MidOcean" or the "Company"), a liquefied natural gas (LNG) company formed and managed by EIG, today announced the conclusion of its 2026 equity capital raise, securing more than $4 billion of closed and pending commitments over the last 12 months from new strategic and institutional investors, as well as significant re-ups from existing investors. The capital committed significantly exceeded the Company's original target of $2 billion, reflecting continued confidence in MidOcean's strategy, portfolio, team and long-term growth outlook. The raise includes commitments from strategic investors, sovereign-linked institutions and financial investors. Among the new investors are the Private Department of Sheikh Mohammed bin Khalid Al Nahyan, Idemitsu Kosan, NYK Line (through Diamond Gas MidOcean), The Arab Energy Fund, Shizuoka Gas and certain Korean institutional investors. The proceeds are expected to enhance MidOcean's balance sheet flexibility and position the Company t
LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion1.10.2026 12:45:00 CEST | Press release
Global research shows oral disease case numbers rose more than 3% over four years, as researchers warn that progress is too slow to meet the WHO’s 2030 target.This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health. Nearly half the world’s population is affected by oral disease – and the number of cases is rising. This World Smile Day, LISTERINE® is launching Oral Care Counts – a multiyear education and advocacy initiative showing why oral health is an essential part of overall health and how practical daily habits, including a three-step oral care routine of brushing, flossing and rinsing, can support better oral health.The multiyear education and advocacy campaign is designed to help more people understand the essential role oral h
Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates1.10.2026 10:30:00 CEST | Press release
The agreement covers SB41, a potential biosimilar candidate referencing Fasenra® (benralizumab), and SB44, a potential biosimilar candidate referencing Ilaris® (canakinumab) with an option for 4 additional assetsThe partnership will cover development and commercialization in the United States, Europe, and Canada, with an option to expand to other territoriesThe partnership brings together Samsung Bioepis’ development, regulatory and manufacturing capabilities with Teva’s global commercial reach to advance the investigational biosimilar candidates and help bring additional important treatment options to patients worldwide Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global license, development, and commercialization agreement for up to six potential biosimilar candidates, with two confirmed investigational biosimilar candidates, SB41, a biosimilar candidate referencing Fasenra®1 (benralizum
FPT and ZEBOX Partner to Advance AI and Sustainable Innovation in Logistics1.10.2026 10:00:00 CEST | Press release
FPT, a global technology and IT services provider, and ZEBOX, the international innovation accelerator initiated by the CMA CGM Group, have entered into a three-year strategic partnership to develop and deploy AI-powered solutions for the transport and logistics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001622214/en/ The partnership was formalized during the Vietnam - France Leaders Forum, held as part of Vietnam’s General Secretary and State President’s official visit to France. The partnership will combine FPT’s expertise in artificial intelligence, automation and large-scale digital transformation with ZEBOX’s innovation network and its close connection to the CMA CGM Group’s global transport and logistics ecosystem. The partners will focus on shipping, port operations, logistics, supply chain management and clean energy. A first joint initiative in Vietnam As a first step, FPT, ZEBOX and CMA CGM Vietnam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom